Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Mavacamten

(Camzyos®)

Camzyos®

Drug updated on 10/24/2024

Dosage FormCapsule (oral; 2.5 mg, 5 mg, 10 mg, 15 mg)
Drug ClassCardiac myosin inhibitors
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of six systematic review(s)/meta-analysis(es). [1-6]
  • Mavacamten significantly improved New York Heart Association (NYHA) class in patients with hypertrophic cardiomyopathy (HCM), with a reduction in NYHA class ranging from 34% to 80% across studies (Documents 4, 5). The pooled analysis showed a significant improvement in clinical response (Log Odds Ratio (OR) = 0.64, p = 0.00).
  • In the hypertrophic obstructive cardiomyopathy (HOCM) subgroup, mavacamten significantly improved the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (Standardized Mean Difference (SMD) = 0.65, 95% Confidence Interval (CI) 0.44-0.87) and peak oxygen consumption (SMD = 0.49, 95% CI 0.24-0.74) (Document 6), although no significant effect was observed in KCCQ overall (SMD = 0.43, p = 0.08).
  • Mavacamten significantly reduced the post-exercise LVOT gradient (p < 0.00001) and N-terminal (NT)-proBNP levels, with three studies confirming the reduction in LVOT gradient.
  • No significant differences were observed in the incidence of severe adverse events or treatment-emergent adverse events between mavacamten and placebo.
  • Decreased left ventricular ejection fraction was noted in some patients, particularly in the hypertrophic obstructive cardiomyopathy (HOCM) subgroup, where the decrease was significant (SMD = -1.14, 95% CI -1.86 to -0.42).
  • Mavacamten demonstrated significant improvements in the hypertrophic obstructive cardiomyopathy (HOCM) subgroup, including enhanced Kansas City Cardiomyopathy Questionnaire (KCCQ) scores (SMD = 0.65, 95% CI 0.44-0.87) and peak oxygen consumption (SMD = 0.49, 95% CI 0.24-0.74), while showing a significant decrease in left ventricular ejection fraction (SMD = -1.14, 95% CI -1.86 to -0.42) in this subgroup (Document 6). There is no population types or subgroups information available in the reviewed documents for other demographic or comorbid subgroups.